Researchers at Washington University School of Medicine in St. Louis have revealed the structure of a key protein involved in ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Researchers from Helmholtz Munich and the Technical University of Munich have developed a novel method to track cancer treatment responses in individual cells—without the need for dyes or labels.

In order to produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic ...

Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy.  The low respo | Cancer ...

The authors proposed two hypotheses: first, that methamphetamine induces neuroinflammation, and second, that it alters neuronal stem cell differentiation. These are valuable hypotheses, and the ...

Molecular glues, tiny molecules that connect one protein to another, are promising targets for pharmaceutical research. By ...

Scientists at ETH Zurich have broken new ground by generating over 400 types of nerve cells from stem cells in the lab, far ...

BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...